Bioversys N
BIOV | SW
Overview
Corporate Details
- ISIN(s):
- CH0210362643 (+1 more)
- LEI:
- 894500UFIGC75NPZEZ68
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.bioversys.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Bioversys N, based in Switzerland, is a biotechnology company focused on developing innovative solutions to combat antibiotic resistance.
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-03 07:00 |
General Meeting Notice
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.6 KB | |
| 2025-06-03 02:00 |
General Meeting Notice
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.0 KB | |
| 2025-04-30 00:00 |
Investor Presentation
BioVersys Corporate Presentation
|
English | 3.2 MB | |
| 2025-04-28 07:00 |
Regulatory News Service
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 8.5 KB | |
| 2025-04-28 02:00 |
Inside Information Statement
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 7.2 KB | |
| 2025-04-08 07:00 |
Regulatory News Service
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
|
English | 29.7 KB | |
| 2025-03-31 07:00 |
Regulatory News Service
BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE
|
English | 11.6 KB | |
| 2025-03-27 07:00 |
Regulatory News Service
BIOVERSYS REPORTS CORPORATE HIGHLIGHTS AND KEY FINANCIALS FOR THE FULL YEAR 2024
|
English | 25.6 KB | |
| 2025-03-27 00:00 |
Regulatory News Service
Webcast Financial Results 2024 & Business update
|
English | 301.8 KB | |
| 2025-03-26 07:00 |
Regulatory News Service
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
|
English | 30.4 KB | |
| 2025-03-26 01:00 |
Regulatory News Service
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
|
English | 27.1 KB | |
| 2025-03-26 00:00 |
Regulatory News Service
BioVersys Annual Report 2024
|
English | 6.9 MB | |
| 2025-03-20 07:00 |
Regulatory News Service
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-…
|
English | 21.0 KB | |
| 2025-03-19 07:00 |
Regulatory News Service
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-…
|
English | 21.0 KB | |
| 2025-03-14 07:00 |
Earnings Release
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVE…
|
English | 6.1 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
| Hiron-Trade Investments & Industrial Buildings Ltd. | Israel | HRON | ||
|
Human Stem Cells Institute PJSC | Russian Federation | ISKJ | |
|
Human Xtensions Ltd. | Israel | HUMX | |
|
Hybrigenics SA | France | ALHYG | |
|
Hyloris Pharmaceuticals SA | Belgium | HYL | |
|
Ikonisys S.A. | France | ALIKO | |
|
IMCB PJSC | Russian Federation | GEMA | |
|
Inify Laboratories AB | Sweden | INIFY | |
|
Innate Pharma | France | IPH | |
|
IntegraGen | France | ALINT |